PDA Options: To view abstract content with the ability to bookmark to set up an itinerary that you can download and save to your PDA or computer, click on MY ITINERARY in the banner above; then proceed by searching the online database.



Sponsored by
Category Index Expand / Collapse All
Click on one of the following letters below to display a list of alphabetized categories.
Click the checkbox next to each item to bookmark.
A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
 A


Expand/Collapse Item Adjuvant Chemotherapy
Expand/Collapse Item Adjuvant Endocrine Therapy
Expand/Collapse Item Adjuvant Therapy - Other
Expand/Collapse Item Adjuvant Therapy - Targeted
Expand/Collapse Item Advanced Chemotherapy
  [80] Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.
  [404] Phase I-II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium trial P7703.
  [6112] Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age.
  [6113] High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials.
  [6114] Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.
  [6115] Weekly paclitaxel versus weekly docetaxel in elderly and frail patients with metastatic breast carcinoma having failed previous anthracyclines: a randomised phase II study of the Belgian Society of Medical Oncology.
  [6116] Randomized multicenter phase II trial of navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first line treatment in HER-2/neu negative metastatic breast cancer patients: updated results.
  [6117] Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.
  [6118] Phase II study of pegylated liposomal doxorubicin (PLD) and carboplatin (Cb) can be administered with trastuzumab (H) in patients with metastatic breast cancer.
  [6119] Carmustine-methotrexate combination in breast cancer patients presenting with brain metastases.
  [6120] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: phase II study.
  [6121] A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study.
  [6122] A multicenter phase II trial of weekly paclitaxel (wPC) and epirubicin (E) in first line metastatic breast cancer (MBC) and pronostic impact of VEGF level.
  [6123] Efficacy of palliative chemotherapy for metastatic breast cancer according to HER2-status and basal cytokeratin expression.
  [6124] A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with doxorubicin as first line treatment of metastatic breast cancer.
  [6125] All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.
 
 

Abstract Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved